Lupride Depot 3.75Mg Injection 1

LUPRIDE DEPOT 3.75MG INJECTION 1 may interact with the following medicines:

• Antiarrhythmic medicines such as amiodarone or quinidine: Concurrent use may increase the risk of QT interval prolongation and serious heart rhythm abnormalities. Patients receiving both medicines may require close cardiac monitoring, especially those with underlying heart disease or electrolyte imbalance.
• Hormonal medicines such as testosterone or oestrogen preparations: Combined use may interfere with the hormone-suppressing effects of leuprolide and reduce its therapeutic effectiveness. This interaction may alter hormonal balance and affect treatment outcomes in hormone-dependent conditions.
• Antidiabetic medicines such as metformin or insulin: Hormonal therapy with leuprolide may affect blood glucose regulation and alter insulin sensitivity in some individuals. Patients with diabetes may require regular blood glucose monitoring and dose adjustments of antidiabetic medicines during treatment.
• Corticosteroids such as prednisolone: Long-term concurrent use may increase the risk of reduced bone mineral density, osteoporosis, and fractures due to additive effects on bone health. Careful monitoring may be required in patients at risk of bone loss.
• Antidepressants such as selective serotonin reuptake inhibitors (SSRIs): Concurrent use may increase the risk of QT prolongation and cardiac rhythm disturbances in susceptible individuals. Caution is advised, particularly in patients with pre-existing cardiovascular conditions or electrolyte abnormalities.

LUPRIDE DEPOT 3.75MG INJECTION 1 may interact with diseases, including:

• Osteoporosis: Long-term use may reduce bone mineral density and increase fracture risk.
• Cardiovascular disease: Patients with heart disease may have an increased risk of arrhythmias or cardiovascular complications during therapy.
• Diabetes mellitus: Hormonal therapy may alter blood glucose levels and require closer monitoring.
• Depression or psychiatric disorders: Mood changes and worsening of underlying psychiatric conditions may occur in susceptible individuals.

The dose and frequency of LUPRIDE DEPOT 3.75MG INJECTION 1 should be determined by your doctor based on the medical condition, treatment response, and hormonal monitoring. Do not alter the prescribed dose without consulting your doctor.

An overdose of LUPRIDE DEPOT 3.75MG INJECTION 1 is unlikely to occur as it is administered by a healthcare professional.

If you miss a scheduled dose of LUPRIDE DEPOT 3.75MG INJECTION 1, contact your doctor or healthcare provider immediately to reschedule the injection. Do not take a double dose to compensate for a missed dose.